Cirrhosis Clinical Trial
Official title:
A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding
Verified date | March 2015 |
Source | Hospital Clinic of Barcelona |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Spanish Agency of Medicines |
Study type | Interventional |
This is a prospective, double blind controlled trial in which patients with esophagic
variceal bleeding treated with standard therapy (endoscopic variceal ligation(EVL) +
B-blockers), will be randomized to receive statins or placebo. They will be followed up
during 12 months to determinate whether statins are effective in prevention of variceal
bleeding recurrence and evaluate patient survival.
Randomization will be stratified according to the degree of hepatic insufficiency, assessed
by the Child-Pugh classifications (A,B or C).
Status | Completed |
Enrollment | 150 |
Est. completion date | September 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients between 18 and 80 years old. - Clinical criteria and/or analytical, ultrasound and/or liver biopsy consistent with the diagnosis of liver cirrhosis. - Hematemesis or melenas within 7 days prior to study inclusion. - Variceal bleeding. Endoscopic diagnosis: - Active variceal bleeding. - Clot or platelet cluster or, - Esophageal varices associated to red blood in esophagogastric lumen in the absence of other sources of bleeding. - Patients with standard treatment for prevention of recurrence of variceal bleeding (EVL+B Blockers,Propanolol). - Women of childbearing age should have a urine pregnancy test negative for 7 days before commencement of treatment and postmenopausal women must have amenorrhea for at least 12 months to be considered not fertile. Potential childbearing women and men must commit to use adequate contraception prior to joining the study and during it. - Written informed consent to participate in the study. Exclusion Criteria: - Pregnancy or lactation - Presence multiple hepatocellular carcinoma or only diameter> 5 cm. - Renal failure ( Creatinine > 2 mg/dl) - Advanced liver disfunction (Child Pugh > 13 points) - Contraindication for statins. - Patients HIV treated with antiretroviral therapy. - Pre-treatment with portosystemic shunt ( surgical or percutaneous). - Bleeding due to gastric varices. - Patients with total portal vein thrombosis or portal cavernomatosis. - Patients previously treated with endoscopic variceal ligation and B- Blockers (before index episode). - Patients previously treated with statins ( one month before the study). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario de Alicante | Alicante | |
Spain | Hospital Clinic | Barcelona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital de la Vall d'Hebron | Barcelona | |
Spain | Hospital German Trias i Pujol | Barcelona | |
Spain | Hospital Universitario del Mar | Barcelona | |
Spain | Hospital Universitari Bellvitge | L´Hospitalet del LLobregat | Barcelona |
Spain | Hospital Arnau de Vilanova | LLeida | Catalunya |
Spain | Hospital Gregorio Marañon | Madrid | |
Spain | Hospital Ramón y Cajal | Madrid | |
Spain | Hospital Puerta del Hierro | Majadahonda | Madrid |
Spain | Complejo Universitario Central de Asturias | Oviedo | Asturias |
Spain | Complejo Hospitalario Pontevedra | Pontevedra | Galicia |
Spain | Corporació Sanitària Parc Tauli | Sabadell | Barcelona |
Spain | Hospital Universitario de Canarias | Tenerife |
Lead Sponsor | Collaborator |
---|---|
Juan A. Arnaiz |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence of variceal bleeding and patient survival | 12 months | No | |
Secondary | Bleeding severity in both arms. | 12 months | No | |
Secondary | Appearance or progression of Portal Hypertension complications | 12 months | No | |
Secondary | Appearance or progression of Portal Vein Thrombosis | 12 months | No | |
Secondary | Need for alternative treatments (transjugular intrahepatic portosystemic shunt [TIPS], surgery) | 12 months | No | |
Secondary | Incidence of adverse events of statin treatment | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT05538546 -
Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A |